Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes

Acta Biochimica et Biophysica Sinica

Volumn 40, Issue 6, 2008, Pages 466-477

  Fei, Qi ^a,b   Zhang, Hongyu ^b   Fu, Lili ^b   Dai, Xinlan ^b   Gao, Baomei ^b   Ni, Min ^b   Ge, Chao ^b   Li, Jinjun ^b   Ding, Xia ^c   Ke, Yuwen ^c   Yao, Xuebiao ^c   Zhu, Jingde ^b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Gene therapy; Hammerhead ribozyme; Hepato cellular carcinoma; Survivin

Indexed keywords

BIRC5 PROTEIN, HUMAN; HAMMERHEAD RIBOZYME; MICROTUBULE ASSOCIATED PROTEIN; RIBOZYME; TUMOR PROTEIN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL SURVIVAL; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; LIVER CELL CARCINOMA; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADENOVIRIDAE; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; GENE SILENCING; GENE THERAPY; GENETIC VECTORS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RNA, CATALYTIC; TRANSFECTION; TREATMENT OUTCOME;

ADENOVIRIDAE;

EID: 45349103627     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2008.00430.x     Document Type: Article

References (26)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100 : 57 70.
2. Salvesen GS, Duckett, CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3 : 401 410.
3. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8 : 61 70.
4. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004, 114 : 1117 1127.
5. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003, 278 : 23130 23140.
6. Schultz IJ, Witjes JA, Swinkels DW, de Kok JB. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin Chim Acta 2006, 368 : 20 32.
7. Parker AS, Kosari F, Lohse CM, Thompson RH, Kwon ED, Murphy L, Riehle DL et al. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer 2006, 107 : 37 45.
8. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001, 108 : 981 990.
9. Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC, Zhu YB et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005, 128 : 361 375.
10. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999, 1 : 461 466.
11. Zangemeister-Wittke U. Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling. Ann N Y Acad Sci 2003, 1002 : 90 94.
12. Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA. Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet 2006, 43 : 119 128.
13. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 2004, 10 : 162 171.
14. Choi KS, Lee TH, Jung MH. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 2003, 10 : 87 95.
15. Sullivan SM. Development of ribozymes for gene therapy. J Invest Dermatol 1994, 103 : 85S 89S.
16. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988, 334 : 585 591.
17. Furue H. Topoisomerase inhibitors developing in Japan. Gan To Kagaku Ryoho 1993, 20 : 42 49.
18. Tanner NK. Ribozymes: the characteristics and properties of catalytic RNAs. FEMS Microbiol Rev 1999, 23 : 257 275.
19. Lieber A, Strauss M. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol 1995, 15 : 540 551.
20. Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Conway EM, Altura RA. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 2005, 24 : 1994 2007.
21. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dorken B, Tamm I. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006, 119 : 1291 1297.
22. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004, 26 : 882 893.
23. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A 2004, 101 : 13239 13244.
24. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003, 3 : 377 383.
25. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7 : 457 468.
26. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 2006, 98 : 1068 1077.